DEVELOPMENT OF SYPHILLIS EIA ASSAYS FOR ORASURE OR SERUM

Information

  • Research Project
  • 6421681
  • ApplicationId
    6421681
  • Core Project Number
    R44AI043808
  • Full Project Number
    6R44AI043808-03
  • Serial Number
    43808
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1999 - 26 years ago
  • Project End Date
    8/31/2002 - 23 years ago
  • Program Officer Name
    SAVARESE, BARBARA M.
  • Budget Start Date
    9/29/2000 - 25 years ago
  • Budget End Date
    8/31/2002 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    3
  • Suffix
  • Award Notice Date
    3/5/2001 - 24 years ago
Organizations

DEVELOPMENT OF SYPHILLIS EIA ASSAYS FOR ORASURE OR SERUM

The objective of the proposed research is to develop a laboratory-based diagnostic system for syphilis to be used on either oral fluid samples or serum/plasma. This system will employ an oral fluid collection device based on the existing FDA approved OraSure HIV-1 Oral Specimen Collection Device which collects an oral sample rich in oral mucosal transudate (OMT). Two enzyme-linked immunosorbent assays will be developed that are compatible with this device to detect both nontreponemal and treponemal antibodies. The nontreponemal assay will measure both IgG and IgM antilipoidal antibodies formed in response to lipoidal material released from damaged host cells early in infection as well as to lipid from the treponeme itself. The antigens used in this assay are biologically nonspecific and are modifications of the Venereal Disease Research Laboratory (VDRL) antigen that contains cardiolipin, cholesterol, and lecithin. The treponemal antibody test will be based on recombinant protein antigens, 17 kDa and TmpA (45 kDa) proteins, derived from the outer membrane of T. pallidum. This system will provide a powerful new tool to expand syphilis testing in the United States. Sample collection will be safe for health care workers and can be accomplished in settings where blood collection is not practical. PROPOSED COMMERCIAL APPLICATIONS: The incidence of syphilis is at an all time low in the US, yet testing levels remain high. In 1998, CDC launched a national syphilis elimination program. The additional funds provided to state and local health departments should expand testing levels. Testing based on a highly sensitive assay system using a noninvasive oral fluid sample will be a valuable tool for the syphilis elimination program.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    6
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    992373
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:992373\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ORASURE TECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BETHLEHEM
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    18015
  • Organization District
    UNITED STATES